A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION) |
Ongoing |
Tezepelumab |
3 |
D5180C00018 |
KAUH-J |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome |
Rejected |
Alogliptin |
3 |
SYR-322_402 |
PSMMC |
A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (pINN Sotorasib) for the Treatment of Subjects with Previously Treated Locally Advanced Unresectable/Metastatic NSCLC with KRAS p.G12C Mutation |
Ongoing |
AMG 510 (Sotorasib) |
3 |
20190436 |
King Fahad Specialist Hospital (Dammam) |
A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer |
Completed |
Pertuzumab + Trastuzumab +Taxane |
3 |
MO28047 |
KFSH & RC-R |
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) |
Completed |
BMN 110 |
3 |
MOR-005 |
KFSH & RC-R |
A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1) |
Completed |
A4250-005 |
3 |
A4250-005 |
KFSH&RC-R |
A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer |
Completed |
Sorafenib |
3 |
BAY43-9006/14295 |
KFSH & RC-R |
A Compartive Multicenter Study of Neoadjuvant Docetaxel/Cisplatin Followed by Concurrent Cisplatin with Radiotherapy using Intensity-Modulated Radition Therapy (IMRT) with or without Bevacizumab for Locally Advanced Nasopharyngeal Cancer |
Completed |
Docetaxel/Cisplatin and Bevacizumab |
3 |
Version 1.3 date 6 may 2012 |
KFMC |
A 96-week, two-arm, randomized, single-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (CONDOR) |
Completed |
Brolucizumab |
3 |
CRTH258D2301 |
DESH |
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation |
Completed |
paliperidone |
3 |
R092670SCH3015 |
JPH |